Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
Leukemia Research, 08/17/2012
Feldman EJ et al. – Single induction response occurred over a 2.3–fold range of doses indicating that CPX–351 may be useful at high doses for patients suitable for intensive chemotherapy and at reduced doses for patients at increased risk of treatment–related mortality. The unique pharmacologic features of CPX–351 contribute to its promising antileukemic efficacy.